Comparative studies on the amoebicidal activity of known 5-nitroimidazole derivatives and CG 10213-Go in golden hamsters, Mesocricetus auratus, infected in the liver or caecum or both with trophozoites of Entamoeba histolytica.
CG 10213-Go, a 5-nitroimidazole derivative synthesized at the CIBA-Geigy Research Centre, Bombay, proved superior to such currently used 5-nitroimidazole derivatives as metronidazole, ornidazole, secnidazole, tinidazole and nimorazole, against experimental amoebic infections of the liver and caecum in a golden hamster model. CG 10213-Go is now undergoing clinical trials.
D000563:Amebicides / Q000627:therapeutic use*; D000818:Animals; D002429:Cecal Diseases / Q000188:drug therapy*; D006224:Cricetinae; D004404:Dysentery, Amebic / Q000188:drug therapy*; D004748:Entamoeba histolytica; D005260:Female; D008101:Liver Abscess, Amebic / Q000188:drug therapy*; D008297:Male; D008647:Mesocricetus; D008795:Metronidazole / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000627:therapeutic use*
D000563:Amebicides; D009593:Nitroimidazoles; D008795:Metronidazole; C034473:satranidazole